16 October 2020 - Did Celgene really request its use for the treatment of non-premenopausal patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer?

It looks like the Department has made a mistake here. Let's see how quickly they correct this.

Contact us if it has been corrected by the time you read this and would like to see the original version.

Read PBAC outcome for ozanimod hydrochloride